Predicting Biomarker of Gastric Cancer Chemotherapy Response

Kyungpook National University Hospital800 enrolled

Overview

* discovery and validation of biomarker predicting gastric cancer chemotherapy response * Analysis for expression level of mRNA using Next generation sequencing in gastric cancer tissue by chemotherapy response * Analysis for expression level of miRNA using Next generation sequencing in gastric cancer tissue and blood by chemotherapy response * Validation of mRNA and miRNA using qRT-PCR in multiple independent cohort * Biological biomarkers-clinical factor combined prediction model of gastric cancer chemotherapy response

* discovery and validation of biomarker predicting gastric cancer chemotherapy response * Analysis for expression level of mRNA in fresh frozen gastric cancer tissue by chemotherapy response (A) method of mRNA expression measurement: RNA sequencing (B) study group Palliative chemotherapy (inoperable patients) * institutional primary Chemotherapy regimen (XP or Xelox) 1. response group 2. progression group Post-OP adjuvant chemotherapy * institutional primary Chemotherapy regimen 1. complete response group 2. non-responder group  1. and 2) groups: age, sex, regimen matched * Analysis for expression level of miRNA using Next generation sequencing in gastric cancer tissue and blood by chemotherapy response (A) method of mRNA expression measurement: RNA sequencing (B) study group * the same patients in mRNA sequencing * Validation of mRNA and miRNA in multiple independent cohort method of measurement of RNA expression: qRT-PCR * Biological biomarkers-clinical factor combined prediction model of gastric cancer chemotherapy response combination of biologic biomarker and clinical factors to predict the chemotherapy response in gastric cancer

Study Type

OBSERVATIONAL

Enrollment

800

Conditions

Gastric Cancer Chemotherapy Effect

Interventions

ChemotherapyDRUG

Institutinal standard chemotherapy as first line : XP (xeloda + cisplantin) or Xelox (xeloda+oxaliplitan) +/- Herceptin

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * new gastric cancer patients who has scheduled to start 1st cycle of chemotherapy * patients who agreed this study and voluntarily assigned the informed consents. Exclusion Criteria: * patients who refused the study. * patients who have other cancers * heavy alcoholics

Locations (1)

Kyungpook National University Medical Canter

Daegu, South Korea

RECRUITING

Outcomes

Primary Outcomes

Discovery of predicting bio-markers for gastric cancer chemotherapy response

Discovery of predicting bio-markers for gastric cancer chemotherapy response using next generation sequencing and qRT-PCR

Time frame: up to 36 months

Secondary Outcomes

Combination prediction model for adjuvant chemotherapy response in gastric cancer

Combination prediction model of biologic biomarkers and clinical factors for the response of adjuvant chemotherapy in gastric cancer

Time frame: up to 5 years

Combination prediction model for palliative chemotherapy response in gastric cancer

Combination prediction model of biologic biomarkers and clinical factors for the response of palliative chemotherapy in gastric cancer

Time frame: up to 3 years

Central Contacts

Su Youn Nam, MD, PhD

CONTACT

82-53-200-2610 nam20131114@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.